HRMY

Over the past six months, Harmony Biosciences' stock price increased by approximately 40.98% since April 9, 2026, with a 52-week trading range between $25.52 and $43.49. Key events included Q1 2026 earnings of $0.550 USD per share and strong Q2 2026 results, where the company reported earnings of $1.28 per share, beating estimates, and revenue of $261.28 million, up 30.3% year-over-year, which led to an 8.9% stock gain. Analyst rating updates included Needham & Company LLC increasing their price target to $50.00 with a 'buy' rating, Wolfe Research initiating coverage with an 'outperform' rating and a $60.00 target, Weiss Ratings upgrading to a 'hold (c+)', Oppenheimer reissuing an 'outperform' rating, and Deutsche Bank Aktiengesellschaft restating a 'hold' rating with a $42.00 price objective. Additionally, insiders sold 72,406 shares valued at $3,108,520 in the last 90 days, including a significant sale by Kumar Budur.